AGP Executive Report
Last update: an hour agoPharma Policy Shock: A sweeping US tariff plan starts Friday, hitting patented brand drugs and imported active ingredients from major companies with a 100% duty unless a qualifying deal is in place, while generics face a staged ramp from 0% through July 31, 2028 to 100% for a year, then 200% thereafter—raising fresh concerns about supply and pharmacy costs. New EU Drug Step: The EMA’s CHMP has issued a positive opinion for NewAmsterdam Pharma’s obicetrapib (Ubeslo®) and the obicetrapib/ezetimibe fixed-dose combo (Evlarco®), moving Europe closer to marketing authorization for certain patients with primary hypercholesterolemia. Medtech Funding in the Region: Healthcare Holding Schweiz AG secured CHF 80 million in syndicated financing, with Liechtenstein’s Landesbank among the lenders, to back further medtech acquisitions and expansion. Health & Benefits Travel Rule: UK PIP recipients are reminded that leaving the country for more than four weeks requires prompt notification to avoid penalties or payment suspension. Local Health Context: A Liechtenstein-linked public service media debate continues after Radio Liechtenstein’s shutdown following a referendum, spotlighting how health-adjacent public information access can be affected.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
